TuHURA Biosciences (HURA)

Executive Summary

TuHURA Biosciences is a Phase 3 immuno-oncology company focused on overcoming primary and acquired resistance to cancer immunotherapies. Its lead candidate, IFx-2.0, is an innate immune agonist being evaluated in a Phase 3 trial for Merkel cell carcinoma (MCC). The company also leverages a VISTA-inhibiting monoclonal antibody (TBS-2025) and a Delta Opioid Receptor (DOR) platform for bispecific antibody-peptide conjugates (APCs) and antibody-drug conjugates (ADCs). With a market cap of ~$155M, TuHURA represents a high-risk, high-reward opportunity in the immuno-oncology space. The upcoming Phase 3 data readout for IFx-2.0 in MCC is a critical value inflection point, while preclinical advancements in TBS-2025 and DOR platform could provide additional upside. However, the company lacks approved products and faces significant clinical and regulatory risks.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 IFx-2.0 data readout in Merkel cell carcinoma40% success
• Q2 2027IND filing for TBS-2025 (VISTA inhibitor)30% success
• Q1 2027Preclinical data update for DOR platform (bispecific APCs/ADCs)25% success